Switzerland· 68290001
Akynzeo IV
A palonosetron, kombinationen product containing fosnetupitantum, palonosetronum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Palonosetron, kombinationen is registered in 11 of 19 countries.
Countries holding a registration under ATC A04AA55 (palonosetron, kombinationen), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 7 of them publish a price we can compare per daily dose
Palonosetron, kombinationen · ATC A04AA55
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of palonosetron, kombinationen costs, country by country.
Normalised to the WHO defined daily dose (0.5 mg), so markets compare like for like.
- Switzerland: $0.20 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Palonosetron, kombinationen · price per daily dose (0.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.20
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- fosnetupitantum, palonosetronum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- A04AA55
- ATC class
- Palonosetron, Kombinationen
- Defined daily dose
- 0.5 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680682900015Durchstf 20 mlCHF 100.95
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palonosetron, kombinationen in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAkynzeo 235 mg / 0.25 mg concentraat voor oplossing voor infusieHelsinn Birex Pharmaceuticals Limited
- United StatesAKYNZEOHelsinn Therapeutics (U.S.), Inc.
- SpainAKYNZEO 235 MG/0,25 MG POLVO PARA CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓNHelsinn Birex Pharmaceuticals Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Akynzeo
- Liechtenstein · Akynzeo
- Norway · Akynzeo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/45193b90-2182-410a-9f79-54438cfccab3 GET /v1/drugs/45193b90-2182-410a-9f79-54438cfccab3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "fosnetupitantum 235 mg + palonosetronum 0.25 mg",
"valid_from": "2024-06-01",
"limitations": "[{\"description\":\"In Kombination mit Dexamethason für Erwachsene:<br>\\n- zur Prävention von akuter und verzögerter Übelkeit und Erbrechen bei stark emetogener zytostatischer Chemotherapie;<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-06-01\",\"validTo\":null}]",
"galenic_form": "Inf Konz 235mg/0.25mg",
"therapeutic_area": null,
"sl_inclusion_date": "2024-06-01",
"self_retention_pct": 10
}See everything about palonosetron, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.